As part of the deal, Paladin will provide the pharma company’s products in some emerging markets such as Latin America, sub-Saharan Africa and Israel. The drugs include Abstral, which is used to treat cancer pain, and anti-nausea patch Sancuso.
Speaking of the licensing deal, Peter Allen, Chairman and acting chief executive “ProStrakan and Paladin already have a track record of working well together.
“I welcome the opportunity to do so more closely as we enter this exciting period in the development of ProStrakan, with US approvals pending for two of our products and the distribution of Sancuso scheduled to re-commence in early 2011.”
Are you looking for a new position in the pharmaceutical industry? Click here to search our current pharmaceutical jobs online now.